FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s

The US FDA has narrowed the use of Biogen/Eisai’s Alzheimer’s treatment Aduhelm (aducanumab), the companies said on July 8, just about a month after it granted the drug polarizing accelerated approval with an unexpectedly broad label. The US regulator has...read more